Surgical perspective in neoadjuvant chemoimmunotherapy for stage II–III non-small cell lung cancer,Thoracic Cancer

当前位置： X-MOL 学术 › Thorac. Cancer › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Surgical perspective in neoadjuvant chemoimmunotherapy for stage II–III non-small cell lung cancer
Thoracic Cancer ( IF 2.3 ) Pub Date : 2021-08-30 , DOI: 10.1111/1759-7714.14127
Tao Hong _{1,

2} , Teng Sun _{1,

2} , Miao Zhang ₃ , Xinlong Liu _{1,

2} , Yanliang Yuan _{1,

2} , Ponnie Robertlee Dolo ₄ , Bi Chen ₅ , Hao Zhang _{1,

2}

Affiliation

There are many studies on neoadjuvant immunotherapy for locally advanced non-small cell lung cancer (NSCLC) patients. Expert consensus recommends neoadjuvant immunotherapy for patients with resectable stage IB–IIIA NSCLC. However, there are few clinical studies or cases to verify this.

中文翻译：